No-Spa Neo (Drotaverine Hydrochloride)

Drotaverine Hydrochloride is an antispasmodic that acts on smooth muscle of the gastrointestinal, genitourinary and biliary systems.

• Abdominal pain and cramps: Reduces intensity of visceral pain by relaxing intestinal smooth muscle.
• Menstrual dysmenorrhea: Alleviates uterine cramps and associated discomfort during menstruation.
• Biliary colic: Relieves spasms of the biliary ducts, easing pain from gallstone obstruction.
• Urinary colic: Decreases ureteral smooth‑muscle spasm, facilitating passage of renal calculi.

• Drotaverine Hydrochloride inhibits phosphodiesterase‑4, leading to accumulation of cyclic adenosine monophosphate (cAMP) within smooth‑muscle cells. Elevated cAMP reduces intracellular calcium concentration, which diminishes contractile activity and promotes relaxation of smooth muscle in the gastrointestinal, genitourinary and biliary tracts. This smooth‑muscle relaxation underlies its antispasmodic effect without significant anticholinergic activity. The drug’s selective inhibition spares other phosphodiesterase isoforms, minimizing systemic side effects.

Drotaverine Hydrochloride may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Dizziness: Light‑headed sensation, especially after standing quickly.
• Headache: Mild to moderate pain in the head region.
• Nausea: Stomach discomfort or urge to vomit.
• Dry mouth: Reduced salivation causing throat dryness.
• Blurred vision: Temporary visual disturbances.
• Fatigue: Unusual tiredness.

Serious or Rare Side Effects

• Allergic reaction: Rash, itching, swelling, or anaphylaxis requiring immediate medical attention.
• Hypotension: Marked drop in blood pressure leading to faintness or shock.
• Cardiac arrhythmia: Irregular heartbeat that may be life‑threatening.

Before prescribing Drotaverine Hydrochloride, clinicians should consider several safety precautions.

• Assess renal and hepatic function: Adjust use if organ impairment is present.
• Monitor blood pressure: Use cautiously in patients prone to hypotension.
• Avoid in known hypersensitivity: Discontinue at first sign of allergic reaction.
• Use during pregnancy only if benefit outweighs risk: Limited data available.
• Avoid in severe cardiac disease: Potential for arrhythmias.
• Store at room temperature: Keep in original packaging, protect from moisture and light.

Drotaverine Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concurrent use with other phosphodiesterase inhibitors: May cause excessive smooth‑muscle relaxation and hypotension.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): May increase drotaverine plasma levels, raising risk of adverse effects.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: Additive blood‑pressure‑lowering effect, monitor BP.
• Anticholinergic drugs: May reduce overall antispasmodic benefit, observe symptom control.
• Alcohol: Can enhance dizziness and hypotensive effects, advise moderation.
• Diuretics: Potential for electrolyte imbalance, watch renal function.